Aparna Group forays into pharma gets USFDA clearance for pharma manufacturing unit

Aparna Pharmaceuticals announced that its manufacturing facility, Aparna Organics, located in Pydibhimavaram, Srikakulalam, Andhra Pradesh, India has received VAI classification from the United States Food and Drug Administration (USFDA). The USFDA audited the facility during the month of September 2023.

Rakesh Reddy, MD, Aparna Pharmaceuticals said, “This clearance is a testament to our team’s relentless pursuit of excellence. Our facility’s compliance journey has been meticulous. We are thrilled to receive the USFDA’s stamp of approval. We are excited to contribute to global healthcare by delivering high quality pharmaceutical APIs and intermediates.”

Aparna OrganicsAparna PharmaceuticalsUSFDAVAI classification
Comments (0)
Add Comment